<p>Granite Bay Wealth Management LLC 在最近向美国证券交易委员会提交的 13F 表格中表示，在第二季度将其在赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE:TMO - 免费报告）的持股增加了 33.1%。该机构投资者在本季度额外购买了 3,395 股后，持有该医疗研究公司 13,667 股股票。赛默飞世尔约占 Granite Bay Wealth Management LLC 持股的 1.8%，使其成为该公司第 22 大持股。截至最近的 SEC 备案，Granite Bay Wealth Management LLC 在赛默飞世尔的持股价值为 5,541,000 美元。</p>
<ul>
<li>现金流关注：赛默飞世尔、能源转移和网易</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也调整了对该股票的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在赛默飞世尔的持股增加了 0.7%。先锋集团目前持有 33,479,957 股该医疗研究公司的股票，价值 16,659,627,000 美元，在上个季度额外购买了 230,382 股。阿穆迪（Amundi）在第一季度将其在赛默飞世尔的持股增加了 5.9%。阿穆迪目前持有 3,029,044 股该医疗研究公司的股票，价值 1,426,316,000 美元，在此期间额外购买了 168,197 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在赛默飞世尔的持股增加了 4.1%。查尔斯·施瓦布投资管理公司目前持有 2,925,591 股该医疗研究公司的股票，价值 1,455,774,000 美元，在上个季度额外购买了 115,463 股。皮克特资产管理控股公司（Pictet Asset Management Holding SA）在第一季度将其在赛默飞世尔的持股增加了 7.2%。皮克特资产管理控股公司目前持有 2,879,274 股该医疗研究公司的股票，价值 1,432,816,000 美元，在上个季度额外购买了 193,378 股。最后，瑞银资产管理美洲有限公司（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度将其在赛默飞世尔的持股增加了 13.6%。瑞银资产管理美洲有限公司目前持有 2,750,923 股该医疗研究公司的股票，价值 1,368,859,000 美元，在此期间额外购买了 329,974 股。89.23% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>内部人士买卖</h2>
<p>在其他赛默飞世尔的新闻中，执行副总裁 Gianluca Pettiti 于 7 月 25 日星期五出售了 400 股该股票。该股票以平均价格 479.98 美元出售，总交易额为 191,992.00 美元。交易完成后，该执行副总裁持有 22,367 股公司股票，价值 10,735,712.66 美元。这代表其持股减少了 1.76%。该出售在与证券交易委员会的法律备案中披露，相关信息可通过此超链接获取。此外，首席执行官 Marc N. Casper 于 8 月 22 日星期五出售了 10,000 股赛默飞世尔的股票。该股票以平均价格 500.96 美元出售，总价值为 5,009,600.00 美元。交易完成后，首席执行官直接持有 115,174 股公司股票，价值 57,697,567.04 美元。这代表其持股减少了 7.99%。该出售的披露信息可在此处找到。在过去 90 天内，内部人士共出售了 30,066 股公司股票，价值 14,182,963 美元。内部人士持有公司股票的 0.33%。</p>
<h2>赛默飞世尔股票表现</h2>
<ul>
<li>安捷伦科技因 “永恒化学品” 打击而蓬勃发展</li>
</ul>
<p>NYSE TMO 周一开盘价为 479.48 美元。该公司的流动比率为 1.93，速动比率为 1.50，债务与股本比率为 0.65。赛默飞世尔的 12 个月最低价为 385.46 美元，最高价为 623.77 美元。该股票的 50 日移动平均线为 466.86 美元，200 日移动平均线为 450.58 美元。该股票的市值为 1,810.6 亿美元，市盈率为 27.73，PEG 比率为 2.56，贝塔值为 0.75。</p>
<p>赛默飞世尔（NYSE:TMO - 获取免费报告）最近于 7 月 23 日星期三公布了其财报。该医疗研究公司报告本季度每股收益为 5.36 美元，超出市场共识预期的 5.22 美元，超出 0.14 美元。赛默飞世尔的股本回报率为 16.82%，净利润率为 15.24%。该公司本季度的收入为 108.6 亿美元，而市场共识预期为 106.8 亿美元。在去年同期，该公司每股收益为 5.37 美元。该公司的季度收入同比增长 2.9%。赛默飞世尔已将其 2025 年第三季度的指引设定为每股收益 5.460-5.510 美元。2025 财年的指引为每股收益 22.220-22.840 美元。卖方分析师预计赛默飞世尔将在当前财年发布每股收益 23.28 美元。</p>
<h2>赛默飞世尔宣布分红</h2>
<ul>
<li>标普 500 中增长最快的 4 只股息股票：买入、卖出还是持有？</li>
</ul>
<p>该公司还最近宣布了一项季度分红，将于 10 月 15 日星期三支付。9 月 15 日星期一的股东将获得 0.43 美元的分红。除息日为 9 月 15 日星期一。这代表每年 1.72 美元的分红和 0.4% 的股息收益率。赛默飞世尔的分红支付比率（DPR）为 9.95%。</p>
<h2>分析师评级上调和下调</h2>
<p>TMO 一直是多份研究报告的主题。Raymond James Financial 在 7 月 24 日的报告中重申了对赛默飞世尔的 “跑赢大盘” 评级，并将其目标价从 525.00 美元上调至 535.00 美元。Robert W. Baird 在 7 月 24 日的报告中将赛默飞世尔的目标价从 553.00 美元上调至 567.00 美元，并给予该股票 “跑赢大盘” 评级。瑞银集团在 7 月 24 日的研究报告中将赛默飞世尔的目标价从 460.00 美元上调至 500.00 美元，并给予公司 “中性” 评级。汇丰银行在 7 月 24 日的研究报告中重申了 “持有” 评级，并对赛默飞世尔的目标价设定为 510.00 美元。最后，富国银行在 7 月 24 日的研究报告中将赛默飞世尔的目标价从 570.00 美元下调至 565.00 美元，并对该公司设定了 “增持” 评级。十七位股票研究分析师对该股票给予了买入评级，五位分析师给予了持有评级。根据 MarketBeat 的数据，赛默飞世尔的平均评级为 “适度买入”，平均目标价为 592.24 美元。</p>
<p><strong>查看我们对赛默飞世尔的最新分析</strong></p>
<h2>关于赛默飞世尔</h2>
<p>（免费报告）</p>
<p>赛默飞世尔科技公司在北美、欧洲、亚太地区及国际市场提供生命科学解决方案、分析仪器、专业诊断、实验室产品和生物制药服务。公司的生命科学解决方案部门为生物和医学研究、药物和疫苗的发现与生产，以及感染和疾病的诊断提供试剂、仪器和耗材；解决方案包括生物科学、遗传科学和生物生产，服务于制药、生物技术、农业、临床、医疗保健、学术和政府市场。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过赛默飞世尔</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>最具性价比？两只上涨潜力超过 30% 的便宜股票</li>
<li>哪里可以找到财报电话会议记录</li>
<li>美式足球赛季来临，DraftKings 股票飙升</li>
<li>交易暂停解析</li>
<li>RH 股票在财报不佳和关税担忧后下滑</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在赛默飞世尔吗？</h2>
<p>在你考虑赛默飞世尔之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而赛默飞世尔并不在名单上。</p>
<p>虽然赛默飞世尔目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

赛默飞世尔

<p>Granite Bay Wealth Management LLC 在第二季度将其在赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE:TMO）的持股增加了 33.1%，目前拥有 13,667 股，价值 554 万美元。其他机构投资者，包括先锋集团（Vanguard）和安盛（Amundi），也增加了他们的持股。内部交易包括执行副总裁 Gianluca Pettiti 和首席执行官 Marc N. Casper 的股票出售。赛默飞世尔的股票开盘价为 479.48 美元，市值为 1810.6 亿美元，最近的每股收益为 5.36 美元，超出预期。该公司报告第二季度收入为 108.6 亿美元，超过预期</p>

<p>Granite Bay Wealth Management LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 33.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,667 shares of the medical research company's stock after acquiring an additional 3,395 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.8% of Granite Bay Wealth Management LLC's holdings, making the stock its 22nd largest holding. Granite Bay Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $5,541,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Granite Bay Wealth Management LLC 在最近向美国证券交易委员会提交的 13F 表格中表示，在第二季度将其在赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE:TMO - 免费报告）的持股增加了 33.1%。该机构投资者在本季度额外购买了 3,395 股后，持有该医疗研究公司 13,667 股股票。赛默飞世尔约占 Granite Bay Wealth Management LLC 持股的 1.8%，使其成为该公司第 22 大持股。截至最近的 SEC 备案，Granite Bay Wealth Management LLC 在赛默飞世尔的持股价值为 5,541,000 美元。</p>
</div><ul>
<li>Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase</li>
</ul>
<div class="lb-trans"><ul>
<li>现金流关注：赛默飞世尔、能源转移和网易</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Thermo Fisher Scientific by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares during the last quarter. Amundi lifted its stake in shares of Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after buying an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after buying an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after acquiring an additional 193,378 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after acquiring an additional 329,974 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也调整了对该股票的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在赛默飞世尔的持股增加了 0.7%。先锋集团目前持有 33,479,957 股该医疗研究公司的股票，价值 16,659,627,000 美元，在上个季度额外购买了 230,382 股。阿穆迪（Amundi）在第一季度将其在赛默飞世尔的持股增加了 5.9%。阿穆迪目前持有 3,029,044 股该医疗研究公司的股票，价值 1,426,316,000 美元，在此期间额外购买了 168,197 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在赛默飞世尔的持股增加了 4.1%。查尔斯·施瓦布投资管理公司目前持有 2,925,591 股该医疗研究公司的股票，价值 1,455,774,000 美元，在上个季度额外购买了 115,463 股。皮克特资产管理控股公司（Pictet Asset Management Holding SA）在第一季度将其在赛默飞世尔的持股增加了 7.2%。皮克特资产管理控股公司目前持有 2,879,274 股该医疗研究公司的股票，价值 1,432,816,000 美元，在上个季度额外购买了 193,378 股。最后，瑞银资产管理美洲有限公司（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度将其在赛默飞世尔的持股增加了 13.6%。瑞银资产管理美洲有限公司目前持有 2,750,923 股该医疗研究公司的股票，价值 1,368,859,000 美元，在此期间额外购买了 329,974 股。89.23% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last 90 days. Insiders own 0.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他赛默飞世尔的新闻中，执行副总裁 Gianluca Pettiti 于 7 月 25 日星期五出售了 400 股该股票。该股票以平均价格 479.98 美元出售，总交易额为 191,992.00 美元。交易完成后，该执行副总裁持有 22,367 股公司股票，价值 10,735,712.66 美元。这代表其持股减少了 1.76%。该出售在与证券交易委员会的法律备案中披露，相关信息可通过此超链接获取。此外，首席执行官 Marc N. Casper 于 8 月 22 日星期五出售了 10,000 股赛默飞世尔的股票。该股票以平均价格 500.96 美元出售，总价值为 5,009,600.00 美元。交易完成后，首席执行官直接持有 115,174 股公司股票，价值 57,697,567.04 美元。这代表其持股减少了 7.99%。该出售的披露信息可在此处找到。在过去 90 天内，内部人士共出售了 30,066 股公司股票，价值 14,182,963 美元。内部人士持有公司股票的 0.33%。</p>
</div><h2>Thermo Fisher Scientific Stock Performance</h2>
<div class="lb-trans"><h2>赛默飞世尔股票表现</h2>
</div><ul>
<li>Agilent Technologies Thrives From the Forever Chemicals Crackdown</li>
</ul>
<div class="lb-trans"><ul>
<li>安捷伦科技因 “永恒化学品” 打击而蓬勃发展</li>
</ul>
</div><p>NYSE TMO opened at $479.48 on Monday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The stock has a 50-day moving average of $466.86 and a 200 day moving average of $450.58. The stock has a market capitalization of $181.06 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.56 and a beta of 0.75.</p>
<div class="lb-trans"><p>NYSE TMO 周一开盘价为 479.48 美元。该公司的流动比率为 1.93，速动比率为 1.50，债务与股本比率为 0.65。赛默飞世尔的 12 个月最低价为 385.46 美元，最高价为 623.77 美元。该股票的 50 日移动平均线为 466.86 美元，200 日移动平均线为 450.58 美元。该股票的市值为 1,810.6 亿美元，市盈率为 27.73，PEG 比率为 2.56，贝塔值为 0.75。</p>
</div><p>Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the company posted $5.37 EPS. The business's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>赛默飞世尔（NYSE:TMO - 获取免费报告）最近于 7 月 23 日星期三公布了其财报。该医疗研究公司报告本季度每股收益为 5.36 美元，超出市场共识预期的 5.22 美元，超出 0.14 美元。赛默飞世尔的股本回报率为 16.82%，净利润率为 15.24%。该公司本季度的收入为 108.6 亿美元，而市场共识预期为 106.8 亿美元。在去年同期，该公司每股收益为 5.37 美元。该公司的季度收入同比增长 2.9%。赛默飞世尔已将其 2025 年第三季度的指引设定为每股收益 5.460-5.510 美元。2025 财年的指引为每股收益 22.220-22.840 美元。卖方分析师预计赛默飞世尔将在当前财年发布每股收益 23.28 美元。</p>
</div><h2>Thermo Fisher Scientific Announces Dividend</h2>
<div class="lb-trans"><h2>赛默飞世尔宣布分红</h2>
</div><ul>
<li>Top 4 Fastest Growing S&amp;P 500 Dividends: Buy, Sell, or Hold?</li>
</ul>
<div class="lb-trans"><ul>
<li>标普 500 中增长最快的 4 只股息股票：买入、卖出还是持有？</li>
</ul>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度分红，将于 10 月 15 日星期三支付。9 月 15 日星期一的股东将获得 0.43 美元的分红。除息日为 9 月 15 日星期一。这代表每年 1.72 美元的分红和 0.4% 的股息收益率。赛默飞世尔的分红支付比率（DPR）为 9.95%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>TMO has been the topic of a number of research reports. Raymond James Financial reissued an &#34;outperform&#34; rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, July 24th. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, July 24th. HSBC reiterated a &#34;hold&#34; rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Wells Fargo &amp; Company decreased their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of &#34;Moderate Buy&#34; and an average target price of $592.24.</p>
<div class="lb-trans"><p>TMO 一直是多份研究报告的主题。Raymond James Financial 在 7 月 24 日的报告中重申了对赛默飞世尔的 “跑赢大盘” 评级，并将其目标价从 525.00 美元上调至 535.00 美元。Robert W. Baird 在 7 月 24 日的报告中将赛默飞世尔的目标价从 553.00 美元上调至 567.00 美元，并给予该股票 “跑赢大盘” 评级。瑞银集团在 7 月 24 日的研究报告中将赛默飞世尔的目标价从 460.00 美元上调至 500.00 美元，并给予公司 “中性” 评级。汇丰银行在 7 月 24 日的研究报告中重申了 “持有” 评级，并对赛默飞世尔的目标价设定为 510.00 美元。最后，富国银行在 7 月 24 日的研究报告中将赛默飞世尔的目标价从 570.00 美元下调至 565.00 美元，并对该公司设定了 “增持” 评级。十七位股票研究分析师对该股票给予了买入评级，五位分析师给予了持有评级。根据 MarketBeat 的数据，赛默飞世尔的平均评级为 “适度买入”，平均目标价为 592.24 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Thermo Fisher Scientific</strong></p>
<div class="lb-trans"><p><strong>查看我们对赛默飞世尔的最新分析</strong></p>
</div><h2>About Thermo Fisher Scientific</h2>
<div class="lb-trans"><h2>关于赛默飞世尔</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.</p>
<div class="lb-trans"><p>赛默飞世尔科技公司在北美、欧洲、亚太地区及国际市场提供生命科学解决方案、分析仪器、专业诊断、实验室产品和生物制药服务。公司的生命科学解决方案部门为生物和医学研究、药物和疫苗的发现与生产，以及感染和疾病的诊断提供试剂、仪器和耗材；解决方案包括生物科学、遗传科学和生物生产，服务于制药、生物技术、农业、临床、医疗保健、学术和政府市场。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Thermo Fisher Scientific</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Football Season Is Here and DraftKings Stock Is Surging</li>
<li>Trading Halts Explained</li>
<li>RH Stock Slides After Mixed Earnings and Tariff Concerns</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过赛默飞世尔</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>最具性价比？两只上涨潜力超过 30% 的便宜股票</li>
<li>哪里可以找到财报电话会议记录</li>
<li>美式足球赛季来临，DraftKings 股票飙升</li>
<li>交易暂停解析</li>
<li>RH 股票在财报不佳和关税担忧后下滑</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TMO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Thermo Fisher Scientific Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在赛默飞世尔吗？</h2>
</div><p>Before you consider Thermo Fisher Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑赛默飞世尔之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而赛默飞世尔并不在名单上。</p>
</div><p>While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然赛默飞世尔目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Granite Bay Wealth Management LLC 购买了赛默飞世尔公司 $TMO 的股票